Ciwon daji
A cikin 'yan shekarun nan, kamuwa da cutar kansar hanta da mace-mace a duniya ya yi yawa. Kasashe masu tasowa suna da kusan kashi 50% na sabbin cututtukan hanta a kowace shekara, kuma yawan kamuwa da cutar sankarau shine na hudu. Duk da haka, yawancin marasa lafiya da ciwon hanta suna hade da cirrhosis, ko kuma mafi yawan marasa lafiya sun kai mataki na gaba a lokacin ganewar asali, kuma kimanin 20% -30% na marasa lafiya na iya samun damar yin aikin tiyata.
Akwai magunguna da yawa don cutar kansar hanta, amma ciwon hanta yana da wuyar magani
Surgery is the only way to cure liver cancer, and only early liver cancer has this opportunity. In addition to surgery, local treatment methods include surgery, transcatheter arterial chemoembolization, percutaneous radiofrequency ablation, and radiation therapy; systemic treatment includes chemotherapy, targeted therapy, and immunotherapy.
With the increasing number of treatments for liver cancer in recent years, precision surgical treatment combined with systemic targeted therapy (sorafenib, lervatinib, regorafenib, cabozantinib and ramozumab) and immunotherapy (Pimumab, Navumab), individualized combination therapy for patients, the treatment effect of advanced liver cancer is greatly improved.
A asibiti, kusan kashi 90% na masu fama da ciwon hanta suna da tarihin ciwon hanta, kashi 5% -8% na marasa lafiya da ciwon hanta suna kamuwa da cutar hanta, kuma kusan kashi 3% na marasa lafiya suna da alaƙa da cirrhosis wanda ke haifar da barasa na yau da kullun, hanta mai kitse. , da cututtukan da ke da alaƙa da cututtukan hanta na autoimmune.
Clinically, the curse of the three-step model (HBV-cirrhosis-liver ciwon daji) has always threatened many domestic liver cancer patients, making many cutting-edge treatment methods unable to improve the current status of liver cancer treatment. New therapies are urgently needed to solve the hepatitis B-related maganin ciwon hanta.
Samar da ƙwayoyin T tare da sabbin takamaiman antigens na makamai
Masu bincike a Asibitin Kasa na Duke-Singapore sun tsara ƙwayoyin cutar Hepatitis B-takamaiman ƙwayoyin T don magance cutar sankarar hanta mai nau'in ciwon hanta B, nau'in ciwon hanta da aka saba gani a Asiya.
Researchers have individualized T cells to make T cells specific to patients. I think this is a CAR-T-like cellular immunotherapy, which is to advance specific antigens of tumo cells by technical means to activate them. T cells, after activated T cells are infused back into the body, it is like updating the weapon scouts to precisely attack cancer cells.
Tawagar ta samu nasarar yi wa wasu majinyata guda biyu da aka yi musu dashen hanta da takamaiman kwayoyin halittar T-cell, wadanda a baya biyu daga cikinsu sun kamu da cutar sankarar hanta da ta haifar da cutar hanta, kuma yanzu sun sake komawa bayan dashen hanta. Bayan takamaiman maganin kwayar cutar T, ɗaya daga cikin marasa lafiya ya ga raguwar mayar da hankali kan ƙari.
Babban antigen shine HBV-DNA
A cikin keɓancewar jiyya, masu bincike sun bincika takamaiman tsarin haɗin kai na HBV-DNA a cikin ƙwayoyin kansa na kowane mai cutar kansar hanta, sannan aka bincika, tsarawa da sarrafa ƙwayoyin T na keɓaɓɓu, sannan a bi da su. Fiye da 20 T-cell an yi nasarar yi a cikin marasa lafiya biyu da aka dasa hanta, kuma waɗannan sel T na injiniya sun iya lalata ciwace-ciwace.
Babban mai bincike, Antonio Bertoletti ya ce: Haɗe-haɗen sashin kwayoyin halittar HBV-DNA na iya kunna ƙwayoyin HBV-takamaiman T sel da kashe ƙwayoyin cutar kansar hanta na musamman ba tare da cutar da sauran ƙwayoyin lafiya ba. Babu wani mummunan halayen da ke da alaƙa da jiyya, kuma ƙwayar cutar kansar hanta mai nisa a cikin majiyyaci ɗaya kuma ya sami raguwa sosai.
Ciwon daji na huhu caused by chronic hepatitis B infection accounts for 80% of all liver cancers in Asian lung cancer, and the treatment prognosis is not ideal. Especially in patients with liver cancer recurrence after liver transplantation, treatment options are more limited.
Ƙayyadadden ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta na iya inganta rayuwa da ingancin rayuwar wannan nau'in majiyyaci. CAR-T cell far sabon bege ne na kayar da cutar kansa a nan gaba!
CAR-T cell far Chimeric Antigen Receptor T-Cell Immunotherapy. Wannan sabon nau'i ne na daidaitaccen maganin da aka yi niyya don magance ciwace-ciwace. A cikin 'yan shekarun nan, ya sami sakamako mai kyau a cikin maganin ciwon daji na asibiti ta hanyar ingantawa da ingantawa. Yana da matukar alƙawarin, daidai, sauri, inganci, kuma mai yiwuwa don warkar da ciwon daji. Sabuwar ƙwayar cuta immunotherapy.
Kuna so karanta: Maganin T-Cell na Mota a Indiya
CAR-T far wata hanya ce ta maganin ciwon daji wacce ta sami ci gaba mai mahimmanci a cikin 'yan shekarun nan, kuma an amince da shi daga sassan duniya masu dacewa don amfani da asibiti a cikin maganin ciwon daji. Bugu da ƙari, gwaje-gwajen asibiti na CAR-T cell far for m ciwace-ciwacen daji suna cikin ci gaba.
